| Code | Description | Claims | Beneficiaries | Total Paid |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
10,133 |
8,076 |
$2.26M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,233 |
4,132 |
$1.79M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
11,354 |
8,991 |
$1.72M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
20,754 |
16,107 |
$445K |
| J3490 |
Unclassified drugs |
14,908 |
5,145 |
$433K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
3,966 |
3,197 |
$422K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
5,280 |
4,216 |
$337K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
7,779 |
2,069 |
$337K |
| 36415 |
Collection of venous blood by venipuncture |
19,689 |
15,212 |
$306K |
| 80053 |
Comprehensive metabolic panel |
10,432 |
8,253 |
$286K |
| 82565 |
|
9,853 |
7,787 |
$206K |
| 82310 |
|
9,172 |
7,356 |
$180K |
| 82947 |
|
9,059 |
7,265 |
$172K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
2,649 |
2,095 |
$168K |
| 84520 |
|
9,111 |
7,293 |
$157K |
| 84132 |
|
9,019 |
7,228 |
$151K |
| 82374 |
|
8,979 |
7,208 |
$149K |
| 82435 |
|
8,978 |
7,208 |
$148K |
| 84295 |
|
8,963 |
7,195 |
$141K |
| 84443 |
Thyroid stimulating hormone (TSH) |
7,168 |
6,254 |
$137K |
| 71046 |
Radiologic examination, chest; 2 views |
2,819 |
2,390 |
$133K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,294 |
2,469 |
$130K |
| 81001 |
|
5,635 |
4,657 |
$128K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,321 |
1,799 |
$117K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,810 |
2,031 |
$116K |
| 82040 |
|
7,283 |
6,006 |
$113K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
4,486 |
3,532 |
$112K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,907 |
2,286 |
$112K |
| 82247 |
|
6,929 |
5,766 |
$105K |
| 84460 |
|
7,258 |
6,019 |
$104K |
| 84450 |
|
7,264 |
6,027 |
$103K |
| 84155 |
|
6,925 |
5,759 |
$99K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,445 |
3,597 |
$95K |
| 84075 |
|
6,917 |
5,763 |
$92K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
763 |
687 |
$84K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
691 |
593 |
$82K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
4,380 |
1,098 |
$74K |
| 84484 |
|
3,540 |
2,062 |
$73K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
2,864 |
2,474 |
$68K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
2,351 |
2,271 |
$67K |
| 80061 |
Lipid panel |
3,410 |
2,903 |
$58K |
| 88142 |
|
3,716 |
3,523 |
$53K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,753 |
3,317 |
$50K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,567 |
1,354 |
$50K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,567 |
1,353 |
$50K |
| G0378 |
Hospital observation service, per hour |
1,607 |
1,344 |
$50K |
| 83690 |
|
2,186 |
1,734 |
$41K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
2,137 |
1,878 |
$41K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,127 |
981 |
$40K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
2,785 |
2,257 |
$38K |
| 84439 |
|
2,360 |
2,085 |
$38K |
| 83735 |
|
2,129 |
1,616 |
$37K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
241 |
213 |
$37K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
416 |
373 |
$37K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
387 |
349 |
$37K |
| 85610 |
|
3,779 |
2,324 |
$36K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
400 |
262 |
$33K |
| 71045 |
Radiologic examination, chest; single view |
1,036 |
868 |
$33K |
| 85027 |
|
2,308 |
1,861 |
$32K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,705 |
1,520 |
$28K |
| 82728 |
|
2,022 |
1,873 |
$24K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
670 |
541 |
$23K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,029 |
1,709 |
$19K |
| 82607 |
|
1,352 |
1,252 |
$19K |
| 83550 |
|
2,259 |
2,083 |
$19K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
455 |
356 |
$18K |
| 80305 |
|
201 |
142 |
$17K |
| 84703 |
|
1,577 |
1,320 |
$16K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
70 |
63 |
$16K |
| 81003 |
|
1,394 |
1,260 |
$16K |
| 83540 |
|
2,285 |
2,106 |
$15K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
192 |
188 |
$15K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,855 |
1,420 |
$14K |
| 83718 |
|
1,686 |
1,601 |
$11K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
1,575 |
1,219 |
$11K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
364 |
318 |
$10K |
| 86140 |
|
829 |
662 |
$7K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,733 |
1,351 |
$6K |
| 83605 |
|
307 |
230 |
$6K |
| 86666 |
|
100 |
90 |
$4K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
88 |
84 |
$4K |
| 86618 |
|
262 |
249 |
$3K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
98 |
62 |
$3K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
24 |
24 |
$3K |
| 85652 |
|
286 |
179 |
$3K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
35 |
33 |
$2K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
61 |
48 |
$2K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
50 |
38 |
$2K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
29 |
27 |
$2K |
| 94664 |
|
281 |
229 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
49 |
42 |
$2K |
| 87186 |
|
69 |
62 |
$1K |
| 82962 |
|
976 |
628 |
$1K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
35 |
12 |
$1K |
| 97162 |
|
29 |
26 |
$1K |
| 87469 |
|
12 |
12 |
$1K |
| 82746 |
|
65 |
65 |
$926.08 |
| 82248 |
|
237 |
206 |
$905.28 |
| 82570 |
|
111 |
85 |
$790.90 |
| 82465 |
|
1,696 |
1,609 |
$650.08 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
318 |
238 |
$597.90 |
| 86900 |
|
18 |
14 |
$576.78 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
18 |
13 |
$561.78 |
| 73562 |
|
16 |
14 |
$542.30 |
| 86038 |
|
31 |
31 |
$451.23 |
| 87070 |
|
112 |
104 |
$425.28 |
| 84478 |
|
1,698 |
1,610 |
$383.50 |
| 86803 |
|
41 |
39 |
$381.64 |
| 82784 |
|
15 |
14 |
$301.83 |
| 73560 |
|
21 |
12 |
$218.52 |
| 87480 |
|
14 |
13 |
$210.65 |
| 87510 |
|
14 |
13 |
$210.65 |
| 87660 |
|
14 |
13 |
$210.65 |
| 81002 |
|
33 |
24 |
$202.76 |
| 82042 |
|
37 |
28 |
$194.90 |
| 85007 |
|
31 |
25 |
$146.16 |
| 84550 |
|
13 |
12 |
$69.10 |
| 83880 |
|
13 |
13 |
$64.84 |
| G0659 |
Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem), excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase), performed without method or drug-specific calibration, without matrix-matched quality control material, or without use of stable isotope or other universally recognized internal standard(s) for each drug, drug metabolite or drug class per specimen; qualitative or quantitative, all sources, includes specimen validity testing, per day, any number of drug classes |
139 |
118 |
$47.89 |
| 87077 |
|
27 |
24 |
$46.32 |
| 87040 |
|
87 |
38 |
$44.61 |
| 85379 |
|
38 |
36 |
$19.44 |
| 85730 |
|
37 |
26 |
$17.19 |
| 82550 |
|
45 |
40 |
$13.17 |
| 81000 |
|
17 |
15 |
$9.06 |
| 87205 |
|
12 |
12 |
$4.07 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
376 |
269 |
$2.27 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
34 |
31 |
$0.00 |
| 96376 |
|
152 |
89 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
118 |
95 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
59 |
51 |
$0.00 |
| 99153 |
Mod sedat endo service >5yrs |
14 |
13 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
93 |
78 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
38 |
25 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
43 |
42 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
12 |
12 |
$0.00 |
| 86901 |
|
18 |
14 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
55 |
49 |
$0.00 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
14 |
12 |
$0.00 |
| 86850 |
|
18 |
14 |
$0.00 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
300 |
260 |
$0.00 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
725 |
584 |
$0.00 |
| 87631 |
|
15 |
13 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
55 |
38 |
$0.00 |